#China #Hangzhou #Hong Kong #medical technology #Zylox-Tonbridge

Zylox-Tonbridge Medical Technology Reports Exceptional 2025 Annual Results

Zylox-Tonbridge Medical Technology Co., Ltd. (HKEX: 2190), a notable name in the medical technology landscape, proudly announced its annual results for 2025, indicating a year of significant growth and success. Based in Hangzhou, China, the company has reported a remarkable revenue of RMB 1.06 billion, marking a year-over-year increase of 35.1%. This robust performance was complemented by an astonishing net profit rise of 143.7% to RMB 244 million, illustrating the effectiveness of its strategic initiatives.

The year 2025 has been characterized by remarkable commercial momentum across their core products and rapid expansion of their international business. One of the standout segments, the neurovascular intervention business, generated RMB 676 million in revenue, an increase of 28.0% from the previous year. Furthermore, the peripheral vascular intervention segment saw even stronger growth, with revenue skyrocketing by 50.3% to reach RMB 379 million.

Zylox-Tonbridge has also made impressive strides internationally, with revenue from markets outside of Mainland China achieving RMB 48.65 million—an impressive leap of 115.5% year-over-year. This success in global market access and channel expansion has reinforced the company’s position as a competitive player in the international medical device arena.

Despite ongoing challenges related to volume-based procurement policies in China, the company managed to maintain a sturdy gross margin of 72.1% in 2025. Coupled with a reported non-IFRS adjusted net profit of RMB 273 million, these results reflect the company's operational efficiency and superior scale.

In a show of confidence in its ongoing success and shareholder value, Zylox-Tonbridge has proposed a final dividend of RMB 0.22 per share for 2025, indicating a payout ratio of approximately 30%. Moreover, the company repurchased shares valued at over HK$130 million in 2025, with intentions to expand share repurchase programs moving forward.

To solidify its long-term growth strategy, the company has been actively engaging in product commercialization and innovation. Zylox-Tonbridge’s sales network has expanded its reach to over 3,300 hospitals throughout China, with cumulative clinical usage of its products surpassing 1.1 million units. Notable product launches during the year included the ZYLOX Mammoth™ Large-Bore Thrombectomy Catheter and the FALCO™ Embolization Assist Stent. Additionally, four innovative products received special review approvals from China’s National Medical Products Administration (NMPA), enhancing the company’s innovative product pipeline.

Zylox-Tonbridge's ambitions don’t stop within the borders of China; the company has been making significant strides in global markets, covering over 80 countries and regions and entering several of the world’s major medical device markets. In 2025 alone, 29 of their products were commercialized across 40 countries, with over 50 additional products in various stages of registration across another 34 countries. This remarkable growth is indicative of an annual compound growth rate of 84% for international revenue over the last four years.

To support this impressive globalization strategy, Zylox-Tonbridge has announced a strategic investment in Germany-based Optimed Medizinische Instrumente GmbH, further strengthening its presence in Europe while aiming to enhance the international commercialization of its innovative offerings. This partnership is set to enhance operational synergies between the two companies, combining resources and expertise from both regions.

Looking to the future, Zylox-Tonbridge is committed to focusing on its dual objectives of innovation and globalization. The company plans to expand its pipeline of clinically differentiated medical products while enhancing its global operational framework to ensure sustainable growth.

Zylox-Tonbridge represents a prime example of how innovation coupled with strategic international expansion can lead to remarkable success in the competitive medical technology market. Founded in 2012, the company embodies its motto, "Innovation for Quality Life," by delivering top-tier medical devices that enhance patient care and access.

For more details about Zylox-Tonbridge and its innovative offerings, visit their official website: www.zyloxtb.com.